Developing Novel Point of Care Diagnostics to Detect SARS-CoV-2
Danilo Tagle,
Associate Director for Special Initiatives,
National Institutes of Health
The National Institutes of Health (NIH) launched the Rapid Acceleration
of Diagnostics (RADx) initiative to meet the needs for COVID-19
diagnostic and surveillance testing, and also to speed its innovation in
the development, commercialization, and implementation of new
technologies and approaches. The RADx Radical (RADx-rad) initiative is
one component of the RADx program which focuses on the development of
new, or non-traditional applications of existing approaches, to enhance
their usability, accessibility, and/or accuracy for the detection of
SARS-CoV-2. This presentation will elaborate on two RADx rad programs
led by the National Center for Advancing Translational Sciences on 1)
pivoting technologies being developed for the isolation of exosomes
towards screening and detection for SARS-CoV-2 viral infection due to
the similar physical and chemical properties between exosomes and
SARS-CoV-2 virus; and 2) developing novel biosensing capabilities using
electronic nose technologies to detect unique signatures of volatile
organic compounds (VOCs) of those with COVID-19 (Screening for COVID-19
by Electronic-Nose Technology (SCENT)).
|
|
